Neuronetics prices $30M public offering, shares slide 13% (STIM:NASDAQ)
Neuronetics (STIM) priced a public offering of 18.75M shares at $1.60 each, expecting ~$30M in gross proceeds. Its shares fell 13% in extended trading. The company also granted underwriters a 30-day option to purchase additional shares.
How this was made
The 30-second read
Why it matters
The dilution and capital raise triggered a 13% drop in extended trading, indicating market concern over share dilution and financing needs.
Market read
The offering is a material corporate action for a small‑cap biotech, creating short‑term trading opportunities.
What to watch
Potential strategic partnership or pipeline progress not disclosed in the brief.
Background
Neuronetics announced a secondary public offering to raise roughly $30M, pricing shares at $1.60 each.
Ticker impact
Neuronetics shares fell 13% in extended trading after pricing a $30M public offering at $1.60 per share.
likely continued downside pressure as the market prices in dilution.
Immediate 13% drop and a sizable dilution event suggest traders will stay cautious on the stock.
Market effects
May raise concerns for other small‑cap neuro‑technology firms about financing conditions.
Limited to U.S. markets; no broader regional effect.
Minimal global impact beyond niche investors.
Counterpoint
If the capital raise funds a breakthrough product, the stock could rebound once milestones are met.
Key entities
- CompanyNeuronetics
Neurostimulation device maker listed on NASDAQ under ticker STIM.

